Determining the association between the type of intervention for ischaemic heart disease and mortality and morbidity in patients with chronic kidney disease

被引:1
|
作者
Jeyaruban, Andrew [1 ,2 ,3 ,4 ]
Hoy, Wendy [1 ,2 ,3 ]
Cameron, Anne L. [1 ,2 ,3 ]
Healy, Helen G. [1 ,2 ,3 ,4 ]
Wang, Zaimin [1 ,2 ,3 ]
Zhang, Jenny [1 ,2 ,3 ]
Mallett, Andrew [1 ,2 ,3 ,4 ]
机构
[1] CKD QLD, Brisbane, Qld, Australia
[2] NHMRC CKD CRE, Brisbane, Qld, Australia
[3] Univ Queensland, Fac Med, Brisbane, Qld, Australia
[4] Royal Brisbane & Womens Hosp, Kidney Hlth Serv, Brisbane, Qld, Australia
基金
英国医学研究理事会;
关键词
non-ST elevation myocardial infarction; chronic kidney disease; end-stage kidney disease; PERCUTANEOUS CORONARY INTERVENTION; CONTRAST-INDUCED NEPHROPATHY; SERUM CREATININE; RISK-FACTORS; REVASCULARIZATION; PATHOPHYSIOLOGY; ANGIOGRAPHY; INCREASES; SURVIVAL; OUTCOMES;
D O I
10.1111/imj.15297
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Association between chronic kidney disease (CKD) and ischaemic heart disease (IHD) is well known. Clinically, because of the use of intra-arterial contrast, coronary angiograms are sometimes not performed to avoid further deterioration in kidney function among CKD patients. Aims To identify whether intervention for non-ST elevation myocardial infarction (NSTEMI) is associated with increased mortality or further renal deterioration. Methods A retrospective observational cohort study involving 144 patients with a diagnosis of IHD in the CKD.QLD registry from May 2011 to August 2017, with a minimum of 2-years follow up, was undertaken. Patients were divided into two groups based on whether they obtained an interventional or medical management for NSTEMI. Results Fifty-nine patients had medically managed and 85 patients had intervention for IHD. Patients in the medically managed group were observed to be significantly older (median: 78 vs 69 years; P < 0.05) with worse baseline renal function (median: 31 vs 36 mL/min/1.73 m(2); P <0.05) and higher serum urate level (median: 0.5 vs 0.4 mmol/L; P = 0.2). The interventional group had lower prevalence of diabetes, dyslipidaemia, cerebrovascular disease and peripheral vascular disease. Although this was not significant, Kaplan-Meier analysis revealed a significant decrease in mean survival of medically managed group compared with the interventional group. Furthermore, post adjustment for age and above comorbidities, the medically managed group and higher age were associated with significantly higher mortality. However, the patients in the medically managed and interventional groups had no significant difference in delta estimated glomerular filtration rate. Conclusions In this observational study, intervention for IHD was associated with increased survival with no change in renal disease progression in comparison with medically managed patients.
引用
收藏
页码:1190 / 1195
页数:6
相关论文
共 50 条
  • [31] Heart Failure Mortality in Chronic Kidney Disease: The Fatal Crossover
    Yeo, Yong-Hao
    San, Boon-Jian
    Mee, Xuan-Ci
    Tan, Min Choon
    Abbas, Amr E.
    Shanmugasundaram, Madhan
    Lee, Justin Z.
    Abidov, Aiden
    Lee, Kwan S.
    AMERICAN JOURNAL OF MEDICINE, 2025, 138 (01):
  • [32] Morbidity and treatment in patients with atrial fibrillation and chronic kidney disease
    Reinecke, Holger
    Nabauer, Michael
    Gerth, Andrea
    Limbourg, Tobias
    Treszl, Andras
    Engelbertz, Christiane
    Eckardt, Lars
    Kirchhof, Paulus
    Wegscheider, Karl
    Ravens, Ursula
    Meinertz, Thomas
    Steinbeck, Gerhard
    Breithardt, Guenter
    KIDNEY INTERNATIONAL, 2015, 87 (01) : 200 - 209
  • [33] Association of Serum Potassium with All-Cause Mortality in Patients with and without Heart Failure, Chronic Kidney Disease, and/or Diabetes
    Collins, Allan J.
    Pitt, Bertram
    Reaven, Nancy
    Funk, Susan
    McGaughey, Karen
    Wilson, Daniel
    Bushinsky, David A.
    AMERICAN JOURNAL OF NEPHROLOGY, 2017, 46 (03) : 213 - 221
  • [34] Nonlinearity association between hyperuricemia and all-cause mortality in patients with chronic kidney disease
    Liu, Ya-Fei
    Han, Liang
    Geng, Yin-Hong
    Wang, Huan-Huan
    Yan, Jia-Hui
    Tu, Sheng-Hao
    SCIENTIFIC REPORTS, 2024, 14 (01)
  • [35] Association between chronic kidney disease and mortality in patients with a confirmed COVID-19 diagnosis
    Betsabe Puicon-Suarez, Jacqueline
    Zena-Nanez, Sandra
    Failoc-Rojas, Virgilio E.
    PEERJ, 2022, 10
  • [36] The association of SBP with mortality in patients with stage 1-4 chronic kidney disease
    Zhuo, Min
    Yang, Danwen
    Goldfarb-Rumyantzev, Alexander
    Brown, Robert S.
    JOURNAL OF HYPERTENSION, 2021, 39 (11) : 2250 - 2257
  • [37] Optimizing the Outcomes of Percutaneous Coronary Intervention in Patients with Chronic Kidney Disease
    Caracciolo, Alessandro
    Scalise, Renato Francesco Maria
    Ceresa, Fabrizio
    Bagnato, Gianluca
    Versace, Antonio Giovanni
    Licordari, Roberto
    Perfetti, Silvia
    Lofrumento, Francesca
    Irrera, Natasha
    Santoro, Domenico
    Patane, Francesco
    Di Bella, Gianluca
    Costa, Francesco
    Micari, Antonio
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (09)
  • [38] Percutaneous coronary intervention in chronic kidney disease patients
    Tadros, GM
    Herzog, CA
    JOURNAL OF NEPHROLOGY, 2004, 17 (03) : 364 - 368
  • [39] Risk Factors for Chronic Kidney Disease in Adult Patients with Congenital Heart Disease and Its Relationship with Cardiovascular Mortality
    Martinez-Quintana, Efren
    Rodriguez-Gonzalez, Fayna
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (22)
  • [40] Association between Free Light Chain Levels, and Disease Progression and Mortality in Chronic Kidney Disease
    Desjardins, Lucie
    Liabeuf, Sophie
    Lenglet, Aurelie
    Lemke, Horst-Dieter
    Vanholder, Raymond
    Choukroun, Gabriel
    Massy, Ziad A.
    TOXINS, 2013, 5 (11) : 2058 - 2073